Press release No. 021/KFCP-DIR/PR/III/22
Jakarta, March 31, 2022 – PT Kalbe Farma Tbk and its subsidiaries (“Kalbe” or “the Company”) today announced that net sales reached Rs 26.261 billion in 2021, growing 13.6% from compared to 2020. Meanwhile, the net income of owners of the parent entity reached Rp 3,184 billion in 2021, increased by 16.5% from Rp 2,733 billion in 2020.
Kalbe continues to innovate to provide products and services in line with community needs and to support sales growth.
The Company strives to provide better access to health care by increasing its contribution to the national health insurance program, launching health products (such as herbal products, supplements and vitamins), more affordable nutritional products and testing and diagnostic services to serve consumers during the Covid-19 pandemic. In addition, to get closer to a wider customer base, the company also provides a B2C – klikdokter (telemedicine) and B2B – EMOS & Mostrans platform through its distribution and logistics divisions. The Company also combines product portfolio management strategies, manages the effectiveness of sales and marketing activities, transforms the use of digital technology and controls other operating costs to maintain profit levels. operation. Additionally, the Company continues to strictly enforce internal and external health protocols and educates the market through various communication channels.
In terms of growth and contribution by division, in 2021, the Distribution and Logistics division achieved an increase in net sales of 25.8% from Rs 7,752 billion to Rs 9,752 billion, and contributed 37.1% to the company’s total net sales. The Prescription Medicines division recorded sales growth of 14.8% from Rs 4,984 billion to Rs 5,719 billion, and accounted for 21.8% of the company’s total net sales. The Consumer Health division achieved a sales increase of 7.1% to Rs 3.623 billion, contributing 13.8% to the company’s total net sales. The Nutrition Division’s net sales amounted to Rs 7,166 billion in 2021, up 2.5% from the prior year’s achievement and accounted for 27.3% of Kalbe’s total net sales in 2021. 2021.
Operating profit increased by 13.1% to reach 4,021 billion rupees in 2021, with an operating profit to sales ratio of 15.3%. Pre-tax profit in 2021 stood at Rs 4,143 billion increased by 14.2% with pre-tax income profit margin reaching 15.6%, stable compared to the same period of the previous year .
Net income of owners of the parent entity reached 3184 billion rupees in 2021, increased by 16.5% from 2733 billion rupees the previous year. The higher growth in net profit compared to the growth in net sales is mainly due to increased efficiency in operating activities.
In 2022, alongside economic recovery and the expected transition from Covid-19 to endemic, the Company is targeting net sales growth of 11% to 15% with expected net profit growth of approximately 11% to 15 %. The company has maintained a capital expenditure budget of Rs 1 trillion, which will be used to expand production and distribution capacity. The dividend payout ratio is maintained at a ratio of 45%-55%, while taking into account the availability of funds and internal financing needs.
The Company’s optimism for growth encourages it to constantly pursue its research and development activities. Through the synergy of ABGC (academic, business, government and community), the company continues to collaborate to produce products and services that can be used by the community (downstream product) and capable of contributing to the business performance of the society. On the other hand, the Company cooperates with various parties, in the form of joint ventures, acquisitions or other forms of business cooperation.
The Company is also innovating through PT Kalbe Genexine Biologics by conducting collaborative research and clinical trials with third parties for Novel products in several countries in Southeast Asia, Australia and the Middle East.
Kalbe at a glance
PT Kalbe Farma Tbk (Kalbe) was established in 1966 and is one of the largest listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that manage trusted and diverse brand portfolios: prescription drugs; health products division which manages over-the-counter drugs; as well as ready-to-drink multivitamins and complementary drinks; nutrition; and distribution and logistics division.
Kalbe has also developed EMOS, an ecosystem of digital services for the community which is B2B; and KlikDokter which is a B2C service. EMOS is an order management application system that allows distribution channels to easily manage inventory or supply chains; while KlikDokter is a digital platform for health services, especially telemedicine that provides health consultations and health products needed by the community.
Kalbe currently has about 40 subsidiaries and 15 production sites with international standards and employs about 16,000 employees in more than 76 branches across Indonesia. Since 1991, Kalbe has been listed on the Indonesia Stock Exchange (IDX: KLBF).